ORLANDO, Fla., Oct. 30, 2024 /PRNewswire/ -- AcariaHealth, a leading national specialty pharmacy and a Centene Corporation company (NYSE: CNC), secured several recognitions during the 2024 National Association of Specialty Pharmacy (NASP) Annual Meeting held in Nashville, Tennessee, October 6-9.
"The honors we received at the conference underscore our commitment to advancing specialty pharmacy and transforming the lives of the patients we serve through compassionate care," said Jessica Ciccolella-Kahl, Chief Executive Officer of AcariaHealth. "Our success is driven by the passion and innovation of our team."
Recognitions
At the NASP Awards, AcariaHealth received several honors, including:
Learn more about the NASP Awards.
Research Presentations
During the conference, AcariaHealth's Vice President of Service Operations, Will Romero, and Pharmacist in Charge, Allison Watson, PharmD, CSP, presented significant research findings on patient adherence through two AcariaHealth poster abstracts:
These presentations highlighted the vital role of personalized support and engagement strategies in improving therapy persistence and adherence rates.
Podcast Feature
Additionally, AcariaHealth was featured in the NASP 2024 Spotlight Series hosted by the Pharmacy Podcast Network. Members of the AcariaHealth leadership team discussed the specialty pharmacy industry, shared insights from recent adherence research, and highlighted free drug programs designed to improve patient access to care. Listen to the podcast episode here.
About AcariaHealth
AcariaHealth is a national specialty pharmacy focused on improving care and outcomes for patients living with complex medical conditions and transforming lives with compassionate care. As a Centene company, AcariaHealth has the unique ability to leverage the comprehensive solutions of the largest Medicaid managed care organization in the country. Visit AcariaHealth.com to learn more about how we provide exceptional specialty pharmacy services and superior patient care.
Last Trade: | US$60.37 |
Daily Change: | 0.02 0.03 |
Daily Volume: | 3,998,309 |
Market Cap: | US$30.480B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB